CD274 and neoplasm: A statistically significant improvement of median PFS (7.5 months with atezolizumab and nab-paclitaxel and 5.0 months with placebo and nab-paclitaxel, HR = 0.62, 95%CI: 0.49-0.78, P < 0.001) was observed in the patients with PD-L1 expression on tumor-infiltrating immune cells (PD-L1 positive subgroup)[123].